Android Coming Soon
In the U.S., where the wireless smart phone market has shifted dramatically with Android owning the largest share (38%) compared to iPhone (27%) and Blackberry (21%) according to Nielsen, Health Discovery Corporation anticipates even greater adoption when it releases an Android version of MelApp. HDC hopes to launch the Android version of MelApp within the next month.
MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center. Using the iPhone camera feature, users can take a picture of their skin lesions and moles and within seconds receive a risk analysis of their uploaded picture being a melanoma. Utilizing your iPhone GPS, MelApp can refer you to a nearby physician specializing in the diagnosis and treatment of melanoma for proper medical follow up, without the need to input a zip code or any personal information. These pictures also can be stored on MelApp and reviewed for changes in the skin lesions occurring over time. MelApp by Health Discovery Corporation launches with a special limited time introductory price of $1.99 and is currently available in the iTunes App Store. More complete details about the mobile health app can be found at http://www.melapp.net and on Facebook http://www.facebook.com/MelApp and Twitter: http://twitter.com/#!/SafeHealthApps.If you are a physician who diagnoses and treats melanoma, and would like to become a subscribed member of our physician referral network, please contact us at firstname.lastname@example.org. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.